Dear Colleagues at #ESMO25 Our Faculty🚨 @AOmlin and @Silke_Gillessen who are chairs of our partners at @APCCC_Lugano 🇨🇭Discuss trials presented here that will be hot topics in Lugano Ping @neerajaiims @tompowles1 @Ecastromarcos @BourlonMaite @cdanicas @nataliagandur

Optimized use of immunotherapy and targeted therapies in #mCRPC. Presentation by @AOmlin. #ESMO25 written coverage by @RKSayyid > bit.ly/47nUjnl @myESMO @neerajaiims

A warm invite to all, we wait for you at #APCCC26 ⭐ Full details & submission apccc.org @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @DrChoueiri @tompowles1 @brian_rini

🧬 Cribriform architecture changes the story in localized prostate cancer. 🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance. 🎯 n = 712 with available slides (13 % cribriform+) 💊 Arms: ▫️ Active monitoring ▫️ Radical prostatectomy ▫️ Radiotherapy + neoadjuvant ADT 📊 Key Results • Cribriform + → ↑ metastasis risk (HR 3.61, 95 % CI 1.60-8.11) • RT + ADT → lowest metastasis (HR 0.35 vs active monitoring) • Surgery → HR 0.52 vs active monitoring (NS) • 15-yr metastasis (cribriform +): AM 25 % | Surg 26 % | RT + ADT 8 % • Cribriform –: 7 % | 4 % | 3 % ✅ Takeaway: Cribriform + = treat aggressively (RT + ADT best long-term control) Cribriform – = active surveillance still safe for most patients. 📖 Sushentsev et al. JAMA Oncology 2025. 🔗 doi.org/10.1001/jamaoncol.20… #OncoTwitter #MedTwitter #ProstateCancer #UroOnc @OncoAlert @myesmo @esmo_open @ASCO @JAMAOnc

Elegant discussion by @Tilki_De reconciling EMBARK & PRESTO #ESMO25: 1. Differences in trial size and 1ry endpoint 2. inclusion criteria close, but pts in EMBARK much higher risk 3. PSMA allowed in PRESTO Important to assess individual risk to select pt for intensification

Great talk by @TylerSbrt about the complementarity of MRI and PSMA PET, and the future of imaging is quantitative #APCCCDiagnostics25 @OncoAlert

🌟 LIVE from #APCCC25! #APCCCDiagnostics25 📢 The PSMA train has left the station… are you on it? 🚆 💡 @DrMHofman delivering brilliant insights on the paradigm shift in prostate cancer imaging! @APCCC_Lugano @OncoAlert 🔍 CT/Bone Scan vs. Next-Gen PSMA PET—how do we adapt clinical decisions? 📊 PSMA PET is redefining detection & treatment planning, leading to earlier and more precise interventions! 🔥 Key Takeaways: ✅ PSMA PET significantly reduces false positives compared to CT/BS (7% vs. 23%) ✅ Better disease delineation → better management decisions ✅ FDG PET/CT helps detect PSMA-negative lesions, improving accuracy 💬 What’s next in imaging? How do we optimize multi-modality approaches for prostate cancer? @ProfKHerrmann @stefanofanti4 @Silke_Gillessen @AOmlin @Albert0Briganti @Ecastromarcos @drlouiseemmett @DrAGafita @karolien_goffin @ProfHadaschik @DrMHofman @Prof_Nick_James @piet_ost @gpalapa2 @MoniqueRoobol @TylerSbrt @DrSpratticus @Tilki_De @BertrandTOMBAL @Nina18205 @UrsulaVogl @ResearchWyatt

When to assess biology with a re-biopsy? Presentation by @mishabeltran @DanaFarber. #APCCCDiagnostics25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4kiSpKm #APCCC25 @APCCC_Lugano

🔥 A FANTASTIC Day 2 at #APCCCDiagnostics25 in Lugano! 🎙️ @Silke_Gillessen 🇨🇭 & @AOmlin 🇨🇭 share their insights on this inaugural edition, highlight key takeaways, unexpected surprises, and already set the stage for #APCCCDiagnostics27! 🚀 Looking ahead to the future of #ProstateCancer diagnostics! @APCCC_Lugano @OncoAlert

The @APCCC_Lugano #APCCC24 Webinar on Management of patients with Advanced #ProstateCancer : Cases from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/ar… ENTIRE WEBINAR HERE in this post @Silke_Gillessen & @AOmlin

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/ar… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors: @Silke_Gillessen @fabioturco92 @Prof_IanD @drjefstathiou Karim Fizazi @Prof_Nick_James Neal Shore Eric Small Matthew Smith @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti Muhammad Bulbul Consuelo Buttigliero Orazio Caffo @cdanicas @Ecastromarcos Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono @mdesantis234 @nachoduranm @EfstathiouEleni Onyeanunam N. Ekeke Tamer I.H. El Nahas @drlouiseemmett @stefanofanti4 Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong @fontev1 @Nicola_Fossati Daniel J. George @marty_gleave Gwenaelle Gravis Susan Halabi Daniel Heinrich @ProfKHerrmann @DrMHofman Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain @BarbaraJereczek Robert J. Jones Anthony M. Joshua @ravikanesvaran Daniel Keizman @FacsRaja Gero Kramer @LoebStacy Brandon A. Mahal Fernando C. Maluf 75 76, @quimmateo David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80, @DrRanaMcKay Niven Mehra 82, @amerseburger @CaPsurvivorship , Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji @declangmurphy Vedang Murthy Shingai B.A. Mutambirwa @DrPaulNguyen William K. Oh @piet_ost Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule @DrSpratticus Sandy Srinivas @cnsternberg Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura @DrYukselUrun Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero @AOmlin

🌍 Just in time for #EarthMonth, check out my new paper “Engaging in Clinical Research & Practice Approaches that Reduce Environmental Impact.” Thx to the team @EurUrolOncol for this opportunity- so many ways we can make a difference! 🌱 Full text link: sciencedirect.com/science/ar…

When Oligometastatix (aka me) and Pelvix (aka @VedangMurthy) share a 3h train ride home from #APCCC24 , new trials are born! Be ready for us #APCCC30! Thanks again @Silke_Gillessen and @AOmlin for having us.

Sad to be leaving #APCCC24 and beautiful Lugano, but what a fantastic meeting it has been. Plenty to think about, and some practice-changing information. Thank you @Silke_Gillessen @AOmlin @APCCC_Lugano for giving me the joy and privilege of being part of such a great community.

Agree, one of the best and most comprehensive talks I have ever heard about the topic- and in 10 minutes! Thanks @heatherhcheng !

💫🌟 #APCCC24 Day 3️⃣ Highlights 🌟💫 @APCCC_Lugano @OncoAlert @Silke_Gillessen @AOmlin 1. 🧬 Dr. Heather Cheng - Urgency of germline testing in advanced prostate cancer. Detecting mutations to open up personalized treatment options. 🔬 #GeneticsInCancer 2. 🌐 Dr. Ana Aparicio - Impact of non-DDR genomic alterations on prostate cancer management. Emphasizes the importance of biomarkers for FDA-approved targeted drugs. #ProstateCancerCare 3. 📊 Dr. Himisha Beltran - Differentiating aggressive variants of castrate-resistant prostate cancer. Stresses the need for combined strategies to address both AR-driven and non-AR-driven diseases. 🧬 #OncologyResearch 4. 🚀 Dr. Andrew Armstrong - Discusses treatment for neuroendocrine and aggressive variants, highlighting platinum combinations and the need for genomic testing for targeted therapies. 🧪 #AdvancedProstateCancer 5. 🛠️ Dr. Matthew Smith - Challenges in sequencing chemotherapy and PSMA radioligand therapy. Discusses the potential superiority of 177Lu-PSMA-617. #CancerTreatment 6. 🔬 Dr. Michael Hofman - Comparison of alternative PSMA ligands for diagnostics and treatment. Equivalence between 68Ga-PSMA-11 and 18F-DCFPyL discussed. #DiagnosticImaging 7. 📝 Dr. Stefano Fanti - Utilizing CT findings in PSMA PET/CT. Discusses challenges with false positives and the importance of acting based on high detection rates of PSMA PET. #MedicalImaging 🌍 Each presentation underscores the crucial need for genomic evaluation and personalized therapy in managing prostate cancer. 👨‍🎓👩‍🎓💬@neerajaiims @ravikanesvaran @scserendipity1 @EfstathiouEleni  @SandhuShahneen @ChrisSweens1 @DrSpratticus @soulehoward1 @nealshore @RobertReiterMD @DRathkopf @ColinCPritchard @piet_ost @WilliamOhMD @ProfJOSullivan @DrPaulNguyen @NDowJames @VedangMurthy @declangmurphy @dmukherji @tompowles1 @brian_rini @mrabti_hind @CaPsurvivorship @DrRanaMcKay @MatikainenMika @quimmateo @LoebStacy @Prof_Nick_James @DrMHofman @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @BraunMDPhD @yekeduz_emre @GGrisay @fabioturco92 @urotoday @ZilliThomas @gu_onc #OncologyUpdate #APCCC2024

And it’s a wrap! It’s been a wonderful and exciting conference. Thanks @Silke_Gillessen @AOmlin and @APCCC_Lugano ! Let’s meet all in 2026 for #APCCC26 And next year for APCCC Diagnostics led by @ProfKHerrmann and @stefanofanti4 #APCCC24

It has been a fantastic @APCCC_Lugano meeting. Already looking forward to APCCC 2026!

Thanks Yüksel, was wonderful to have you with us!